Icatibant Newbury (Icatibant)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The dose of Icatibant Newbury is determined by the prescribing clinician based on the patient’s condition and clinical guidelines. The prescriber will specify the amount, frequency, and duration of treatment.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑inhibitor concentrates replace the deficient protein. Icatibant provides a rapid, receptor‑targeted approach and is administered subcutaneously, offering an alternative for patients who prefer or require a non‑intravenous option.

Icatibant Newbury should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

The medication is supplied as a solution for injection and is administered subcutaneously, typically into the abdomen or thigh. The injection is performed by a healthcare professional or trained patient following the prescriber’s instructions.

Serious risks include anaphylaxis, severe hypotension, and rare cases of angioedema or thrombocytopenia. Patients should be monitored for signs of allergic reaction or sudden blood pressure changes after administration.

Icatibant is contraindicated in patients with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for individuals taking ACE inhibitors, neprilysin inhibitors, or estrogen‑containing therapies due to potential additive bradykinin effects.